Does Waters Corporation (WAT) have an economic moat?

MoatScan AI rates Waters Corporation (WAT) 56/100 for moat strength, assessed across five sources of competitive advantage: network effects, switching costs, intangible assets, cost advantages and efficient scale. Waters has a real but fairly concentrated competitive advantage built around high-performance liquid chromatography, mass spectrometry, consumables, and the software and workflows that sit around those instruments.

What is Waters Corporation's moat score?

Waters Corporation (WAT) has a moat score of 56/100. The score is a weighted average of five pillar ratings: network effects, switching costs, intangible assets, cost advantages, and efficient scale. A higher score means the competitive advantages MoatScan AI identifies are wider and more durable.

Is WAT stock overvalued or undervalued?

MoatScan AI answers this by estimating WAT's intrinsic value with a EV/EBITDA model, then comparing that estimate to the current market price. A share price meaningfully below the estimate is flagged undervalued; meaningfully above it, overvalued. The estimate updates with each new financial analysis.

What is Waters Corporation's fair value estimate?

MoatScan AI derives Waters Corporation's (WAT) fair value per share from a EV/EBITDA model built on the company's reported financials, analyst growth forecasts, and a discount rate reflecting its cost of capital. The Financial Analysis tab shows the estimate alongside every assumption behind it.

Back to Database

WAT$304.24

Waters Corporation

Last Updated

Jul 29, 202630 days ago

Moat & Trend

Management

AI Impact

Competitive Radar

Moat Score

56/100

Executive Summary

Waters has a real but fairly concentrated competitive advantage built around high-performance liquid chromatography, mass spectrometry, consumables, and the software and workflows that sit around those instruments. Its strongest economic defense comes from switching costs: once a lab validates methods, trains staff, and embeds Waters software and service into regulated workflows, replacement is disruptive and risky. The brand is also well regarded in analytical science, and the company benefits from a specialized, globally supported installed base. However, Waters lacks meaningful network effects and does not enjoy a true cost advantage versus larger diversified rivals such as Thermo Fisher, Danaher, or Agilent. The moat is therefore durable but narrow rather than wide. Recent portfolio expansion should support resilience, but integration and competition keep the overall trend stable rather than clearly improving.

Network Effects

Limited Ecosystem Reinforcement

Pillar Strength

3/10

Waters does not benefit from strong classical network effects because the value of its instruments does not rise materially as more labs adopt them. Each customer primarily buys for its own workflow, regulatory, and performance needs, not because a larger user base creates a self-reinforcing marketplace. There is some indirect ecosystem benefit from installed software, method sharing, training familiarity, and third-party service knowledge, but these effects are modest and do not materially lock in new buyers. Laboratories can and do multi-home across vendors, especially across chromatography and mass spectrometry categories. That keeps the network component real but weak, more a brand and standards effect than a true participant-driven network moat.

Switching Costs

Validated Workflow Lock-In

Pillar Strength

8/10

Switching costs are Waters’ clearest moat pillar. Analytical labs often build validated methods, instrument qualification routines, service relationships, and data workflows around a specific platform, especially in regulated pharmaceutical, biotech, and food-testing environments. Replacing a Waters system can require retraining staff, revalidating methods, changing software integrations, and accepting the risk of downtime or compliance issues. Consumables and service add further inertia because recurring purchases and maintenance plans are tied to the existing installed base. While customers can switch in a cost-conscious environment, the practical disruption is meaningful enough that most only do so when performance, price, or procurement pressures justify the effort. That creates durable retention and recurring revenue.

Intangible Assets

Respected Scientific Brand

Pillar Strength

7.5/10

Waters possesses meaningful intangible assets in the form of a respected scientific brand, a long operating history, proprietary product families, and accumulated technical know-how. Names such as ACQUITY, Empower, and Xevo carry credibility in laboratories that care deeply about separation performance, reproducibility, and compliance support. The company also benefits from patents, method expertise, and a reputation for helping customers solve difficult analytical problems. These assets are not absolute barriers, because rivals can invest in comparable technology and sales support, but Waters’ credibility was built over decades and cannot be quickly copied. The result is durable trust-based pricing power in specialized niches, even if it is narrower than the brand power of a broad-life-sciences conglomerate.

Cost Advantages

Moderate Scale Benefits

Pillar Strength

4/10

Waters has some cost advantages from scale in manufacturing, service, and consumables distribution, but they are not sufficiently strong to define the moat. The company operates in a technically demanding market where product quality, application support, and regulatory credibility matter more than pure unit cost. Large rivals such as Thermo Fisher, Danaher, and Agilent have comparable or greater scale, and all can invest heavily in R&D, field service, and global supply chains. Waters can spread development and support costs across a meaningful installed base, which helps margins, but there is little evidence of a structurally lower-cost position that rivals cannot match. In practice, cost is a competitive variable, not a decisive structural edge.

Efficient Scale

Specialized Oligopoly Position

Pillar Strength

5.5/10

Waters operates in a specialized segment of the life-sciences tools market where a handful of large vendors dominate high-end chromatography and mass spectrometry. That structure creates some efficient-scale benefits: customers prefer suppliers with deep applications support, global service coverage, and the financial strength to support long product lifecycles. For certain niche workflows, the market is not large enough to support many fully scaled entrants, which helps established players. Still, this is not a natural monopoly or a tightly regulated utility-like environment. Large, well-capitalized rivals remain active and credible, and customers can source broadly similar capabilities from alternative platforms. So Waters has meaningful but limited scale protection, more oligopolistic than monopolistic.

Management Quality Assessment

Evaluating leadership track record, capital allocation, and governance

Verdict

Competent

Udit Batra has led Waters since September 2020 and previously ran Merck KGaA’s life-science business, but at Waters his record is mixed: ROIC has fallen to about 16% from a 2022 peak near 29%, while buybacks have not offset dilution, leaving shareholder yield negative. The company is not founder-led; it is run by hired management, and the board is largely independent, which helps oversight. Insider ownership appears low, with the CEO owning about 0.026% and directors holding small stakes. CEO pay of about $14 million in 2025 looks rich versus recent performance, though governance red flags are limited beyond pay alignment.

Key Highlights

CEO Udit Batra has run Waters since September 2020 and brought prior operating experience from Merck KGaA and Novartis, giving the company an experienced external operator rather than a founder-led structure.
Capital efficiency has softened: ROIC is roughly 16% versus a three-year median near 19% and a 2022 peak around 29%, suggesting weaker value creation on new capital.
Share repurchases have not translated into net shareholder-friendly capital returns; overall shareholder yield is negative because dilution and other equity issuance have offset buybacks.
Waters’ board and key committees are largely independent, which supports governance quality and reduces the risk of entrenched control.
Insider ownership is modest, and the CEO’s roughly 0.026% stake is small relative to his approximately $14 million 2025 compensation, pointing to only moderate alignment.

AI Impact Assessment

Evaluating how AI strengthens or disrupts existing moat pillars

AI Opportunity

6/ 10

AI Threat

4/ 10

Net AI Impact

+2Moderate Tailwind

Net Neutral. AI should reinforce Waters’ position more than transform it because the company’s moat already rests on installed instruments, validated workflows, service, and regulatory trust rather than software alone. AI can deepen lock-in by improving peak detection, method development, predictive maintenance, and informatics across Empower, MassLynx, and Waters Connect, but those gains mainly defend existing workflows. The strongest advantage is proprietary, domain-specific data generated by a large regulated customer base, which generic models cannot easily replicate. The main uncertainty is whether AI materially expands Waters’ software attach rate and consumables pull-through, or merely becomes a standard feature that competitors also bundle into comparable platforms.

AI Opportunity Highlights

AI can increase switching costs by embedding analytics into validated Empower, MassLynx, and Waters Connect workflows that customers are reluctant to requalify.
Waters’ large base of chromatography and mass-spectrometry data can support domain-specific models for peak detection, method optimization, and anomaly detection.
Predictive maintenance models can improve uptime and strengthen service attach rates across the installed instrument base.
AI-enabled process optimization can deepen Waters’ role in regulated pharmaceutical and food-testing environments where validated outputs matter more than generic automation.
The IMU Biosciences collaboration shows a path to extend Waters’ analytical stack into higher-value biomarker and immune-mapping applications.

AI Threat Highlights

Routine chromatographic and mass-spec data interpretation is increasingly automatable, which can compress pricing power in software and services.
AI-native analytics vendors can unbundle parts of the workflow from Waters hardware, weakening the stickiness of the installed base.
Open-source tools and foundation models lower the barrier for labs to build their own method-development and QC pipelines.
If competitors validate AI features faster in regulated settings, Waters could lose share in software-led workflow decisions even if hardware remains strong.

Sign in to see the full analysis

The Strategic Factor Breakdown, Management Quality Assessment, and AI Impact Assessment are available to registered users — it's free.

Last Updated

Apr 3, 20265 months ago

Target Price

Analyst Consensus

FAIR VALUE

Financial Strength

Financial Score

69/100

Executive Summary

Waters Corporation exhibits a robust financial profile underpinned by a significantly strengthened balance sheet and improving leverage. While revenue growth has been inconsistent, with recent dips, it is projected to rebound strongly, supported by healthy gross margins and a solid backlog. Operating margins have compressed due to rising expenses, but efficient cash flow generation, particularly positive free cash flow, demonstrates operational strength. The company's liquidity has slightly decreased but remains reasonable, and while asset turnover has declined, profitability ratios like ROE and ROIC, though normalized from peak levels, remain healthy. Positive analyst sentiment and projected strong EPS growth further bolster confidence in its trajectory, positioning Waters Corporation for continued financial stability and growth.

Income Statement

Revenue · Margins · Profitability

Section Score

6.5/10

Waters Corporation demonstrates inconsistent growth, with revenue growth fluctuating from 17.78% in FY21 to near flat in FY23 and FY24, before recovering to 6.99% in FY25. Net income growth also shows volatility, with declines in FY23 and FY24. Gross margins are consistently strong, hovering around 58-59%, indicating efficient cost of revenue management. However, operating margins have compressed from 29.5% in FY21 to 25.36% in FY25, primarily due to rising operating expenses, particularly selling, general & administrative costs. There are no significant one-off items skewing earnings, suggesting the observed trends reflect structural shifts. Assuming Waters Corporation operates in the specialized laboratory equipment and software sector, these margins are respectable, but the declining operating margin is a concern. The primary risk is the sustained increase in total operating expenses outpacing revenue growth, leading to overall profitability erosion despite stable gross margins. This trend warrants close monitoring to assess if it's a short-term investment phase or a sustained pressure on operational efficiency.

Financials are in millions USD unless otherwise specified

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	3,165	2,958	2,956	2,972	2,786
Revenue Growth (YoY)	6.99%	0.07%	-0.52%	6.68%	17.78%
Net Income	642.63	637.83	642.23	707.76	692.84
Net Income Growth	0.75%	-0.69%	-9.26%	2.15%	32.84%
Profit Margin	20.30%	21.56%	21.72%	23.81%	24.87%

Data as of Dec 31, 2025

Balance Sheet

Assets · Liabilities · Equity

Section Score

7.5/10

Waters Corporation demonstrates a generally healthy balance sheet, though recent trends warrant attention. Total current assets have shown growth from $1,629 million in FY2021 to $2,148 million in FY2025, while total current liabilities also increased from $680.51 million to $1,239 million over the same period, suggesting some tightening of short-term liquidity, especially with the increase in short-term debt in FY2025. Total assets have expanded robustly from $3,095 million to $5,077 million. Total liabilities, while increasing from $2,727 million to $3,477 million by FY2023, have notably decreased to $2,515 million in FY2025, driven by a reduction in long-term debt. Shareholders' equity has shown consistent and strong growth, more than doubling from $367.55 million to $2,561 million, indicating improved solvency and asset quality. The significant increase in goodwill and other intangible assets from FY2022 to FY2023 indicates substantial acquisition activity. Overall, the company maintains a solid equity base and has improved its leverage profile recently.

Financials are in millions USD unless otherwise specified

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Current Assets	2,148	1,669	1,753	1,764	1,629
Total Assets	5,077	4,554	4,627	3,281	3,095
Total Current Liabilities	1,239	789.76	789.58	785.74	680.51
Total Liabilities	2,515	2,725	3,477	2,777	2,727

Data as of Dec 31, 2025

Cash Flow Statement

Operations · Investing · Financing

Section Score

6.5/10

Waters Corporation's operating cash flow (CFO) has shown some volatility, with growth ranging from -18.15% in FY 2022 to 26.43% in FY 2024. While capital expenditures have been consistently negative, indicating ongoing investment, they have also shown a decreasing trend, which is positive for FCF. Free cash flow (FCF) has been positive across all periods, reaching a high of $619.64 million in FY 2024, demonstrating consistent cash generation after capital reinvestment. FCF margin has also remained healthy, averaging around 17.7% over the last five years. However, significant swings in financing activities, including large debt issuances and repayments, alongside fluctuating share repurchases, suggest a dynamic capital allocation strategy that warrants continued monitoring. The large payment for business acquisitions in FY 2023 also impacted overall cash flow.

Financials are in millions USD unless otherwise specified

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow	652.56	762.12	602.81	611.66	747.27
Operating Cash Flow Growth	-14.38%	26.43%	-1.45%	-18.15%	-5.47%
Free Cash Flow	539.81	619.64	442.18	435.74	586.01
Free Cash Flow Growth	-12.88%	40.13%	1.48%	-25.64%	-5.20%

Data as of Dec 31, 2025

Key Ratios

Liquidity · Leverage · Efficiency · Returns

Section Score

7/10

Waters Corporation demonstrates good financial health. Liquidity, as indicated by the current ratio, has slightly declined from 2.24 to 1.73 over the period, suggesting some reduction in short-term coverage, although still reasonable. Leverage has shown significant improvement, with the Debt/Equity ratio decreasing substantially from 3.24 to 0.57, indicating a stronger capital structure and reduced reliance on debt. Efficiency metrics like asset turnover have seen a decline from 0.93 to 0.68, suggesting a less productive use of assets over time, while inventory turnover has also decreased. Profitability and returns, particularly ROE and ROIC, have trended downwards from very high levels in 2022 (ROE 162.32%, ROIC 31.3%) to more moderate but still healthy levels (ROE 33.12%, ROIC 19.05% currently), reflecting a normalization rather than a severe deterioration.

Ratios are dimensionless unless otherwise noted

Metric	Current	FY 2025	FY 2024	FY 2023	FY 2023	FY 2022
Period Ending	Apr 2, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Sep 30, 2023	Dec 31, 2022
Debt / Equity Ratio	0.57	0.57	0.92	2.1	—	3.24
Quick Ratio	1.14	1.14	1.34	1.39	—	1.53
Current Ratio	1.73	1.73	2.11	2.22	—	2.24
ROEReturn on Equity (ROE)	33.12%	29.28%	42.82%	77.62%	0.00%	162.32%
ROAReturn on Assets (ROA)	16.02%	14.19%	15.21%	18.04%	0.00%	23.14%
ROICReturn on Invested Capital (ROIC)	19.05%	16.87%	17.88%	22.28%	0.00%	31.30%
ROCEReturn on Capital Employed (ROCE)	23.86%	21.12%	21.74%	25.82%	0.00%	35.58%

Data as of Apr 2, 2026

Growth

Revenue · EPS · Valuation · Estimates

Section Score

7/10

Waters Corporation demonstrates a mixed growth profile, with a recent dip in 2023-2024 followed by a strong recovery projected from FY2025. Historical revenue growth was robust in FY2021 (17.78%) and FY2022 (6.68%) but turned negative in FY2023 (-0.52%) and remained flat in FY2024 (0.07%). However, analyst estimates project significant revenue acceleration, reaching 104.66% in FY2026 and 10.53% in FY2027. EPS growth shows a similar pattern of contraction in 2023-2024 but an expected rebound in 2026-2027, with 35.05% and 13.1% respectively, outpacing revenue in some periods, suggesting potential margin expansion. Forward P/E multiples of 20.94x for FY2026 and 18.51x for FY2027 appear reasonable given the substantial anticipated growth. Analyst sentiment is positive, with a 'Buy' consensus from 16 analysts, and the recommendation trend shows a slight improvement in 'Strong Buy' and 'Buy' ratings from Nov '25 to Mar '26, indicating increasing conviction.

Analyst Price Targets

Low$325+6.82%

Median$385+26.54%

Average$387.31+27.30%

High$480+57.77%

BuyConsensus rating based on analyst coverage

16 analysts

Recommendation Trends

Rating	Mar '26	Mar '26	Feb '26	Jan '26	Dec '25	Nov '25
Strong Buy	4	4	4	3	2	2
Buy	5	5	5	5	4	3
Hold	8	8	9	9	9	8
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	17	17	18	17	15	13

Financial Forecast

Metric	FY 2027	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	7.16B	6.48B	3.17B	2.96B	2.96B	2.97B	2.79B
Revenue Growth	+10.53%	+104.66%	+6.99%	+0.07%	-0.52%	+6.68%	+17.78%
EPS	16.44	14.53	10.76	10.71	10.84	11.73	11.17
EPS Growth	+13.10%	+35.05%	+0.47%	-1.20%	-7.59%	+5.01%	+33.61%
Forward P/E	18.5x	20.9x	—	—	—	—	—

Revenue in USD · EPS per share · Price targets in USD

Data as of FY 2025 · Italic columns are analyst estimates

Fair Value Estimation

EV/EBITDA · +16.4% Margin of Safety · Undervalued

AI Fair Value Estimate (EV/EBITDA)

$353.96vs$304.24

Margin of Safety+16.4%

Undervalued — Margin of safety detected

Waters Corporation is a mature, profitable company in the life sciences tools and analytical instrumentation sector with stable, positive EBITDA and significant capital expenditures, making EV/EBITDA an appropriate valuation model. This approach accounts for different capital structures and non-cash expenses like depreciation and amortization, which can be substantial in capital-intensive businesses.

AI Valuation Verdict

Waters Corporation is a prominent player in the life sciences tools industry, exhibiting consistent profitability and significant capital expenditures. The EV/EBITDA multiple is the most suitable valuation model, as it accounts for varying capital structures and the impact of depreciation in this capital-intensive sector. We estimate a fair value per share of $353.96, suggesting the stock is undervalued with a 16.35% margin of safety. This estimate is derived from an average of comparable companies' EV/EBITDA multiples, adjusted for Waters' specific financial profile. Key sensitivities include the selection of comparable companies and their prevailing multiples, as well as Waters' future EBITDA generation. A higher industry multiple or stronger-than-expected EBITDA growth could further increase the fair value. Analyst consensus generally rates WAT as a 'Buy,' with a median price target above our fair value, indicating alignment with our undervaluation assessment. However, some analysts have lower price targets, suggesting potential risks related to competitive pressures or market slowdowns.

Comparable Companies

Company	Ticker	Metric	Multiple	Implied Price
Agilent Technologies	A	EV/EBITDA	17.88	$361.32
PerkinElmer Inc.	PKI	EV/EBITDA	16.17	$326.83
Shimadzu Corporation	SHMZF	EV/EBITDA	11.6	$234.33

Sign in to see the full analysis

The Income Statement, Balance Sheet, Cash Flow, Key Ratios, Forecast, and Fair Value analysis are available to registered users — it's free.

Sign In to Run AI-Powered Technical Analysis

Create a free account to run a fresh technical analysis across three timeframes — short, medium, and long term.

Frequently asked questions about Waters Corporation

Does Waters Corporation (WAT) have an economic moat?: MoatScan AI rates Waters Corporation (WAT) 56/100 for moat strength, assessed across five sources of competitive advantage: network effects, switching costs, intangible assets, cost advantages and efficient scale. Waters has a real but fairly concentrated competitive advantage built around high-performance liquid chromatography, mass spectrometry, consumables, and the software and workflows that sit around those instruments.Sign in free to see the Moat Type verdict and the pillar-by-pillar reasoning.
What is Waters Corporation's moat score?: Waters Corporation (WAT) has a moat score of 56/100. The score is a weighted average of five pillar ratings: network effects, switching costs, intangible assets, cost advantages, and efficient scale. A higher score means the competitive advantages MoatScan AI identifies are wider and more durable.Sign in free to see each pillar rating, the Moat Type verdict and the moat trend.
Is WAT stock overvalued or undervalued?: MoatScan AI answers this by estimating WAT's intrinsic value with a EV/EBITDA model, then comparing that estimate to the current market price. A share price meaningfully below the estimate is flagged undervalued; meaningfully above it, overvalued. The estimate updates with each new financial analysis.Sign in free to see the fair value estimate, the implied upside or downside, and the verdict.
What is Waters Corporation's fair value estimate?: MoatScan AI derives Waters Corporation's (WAT) fair value per share from a EV/EBITDA model built on the company's reported financials, analyst growth forecasts, and a discount rate reflecting its cost of capital. The Financial Analysis tab shows the estimate alongside every assumption behind it.Sign in free to see the estimate and the full assumptions behind it.

Disclaimer: The analysis on this page is generated by AI and is provided for informational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any security. Always conduct your own due diligence and consult a qualified financial adviser before making any investment decisions.

WAT$304.24

Sign in to see the full analysis

Sign in to see the full analysis

Sign In to Run AI-Powered Technical Analysis

Frequently asked questions about Waters Corporation

Other Narrow Moat companies